Latisse or OTC Eyelash Growth Serum? Check for the Unapproved Cousin

Latisse is a prescription drug for eyelash growth, bimatoprost 0.03%, not a cosmetic lash serum. The American Academy of Ophthalmology (AAO) lists it as bimatoprost ophthalmic solution, 0.03%, and says it is FDA approved. Over-the-counter serums often use a different prostaglandin analog, isopropyl cloprostenate, which the AAO says is not FDA approved.

If you want a prostaglandin lash serum, go the prescription route: brand Latisse, or generic bimatoprost 0.03% from an online prescriber such as Wisp. If a permanent change in eye color is a risk you won’t take, skip serums altogether. False lashes or extensions are the alternative, and the FDA classes them as cosmetics.

This is not medical advice. A prescriber decides whether bimatoprost is right for you.

See an eye doctor first if you have an eye condition. The AAO says to talk with an ophthalmologist before using Latisse if you have glaucoma, macular edema or eye inflammation. If you develop any eye reaction or a sudden decrease in your vision once you start, the AAO says to call your ophthalmologist immediately.

Latisse is bimatoprost 0.03%, sold by prescription only

Latisse’s home page prints “PRESCRIPTION ONLY” beside its before-and-after photos. It adds two caveats: the people shown are “Paid users,” and “Results may vary” (Latisse.com, checked October 2026).

The weak spot is right there in the fine print. You cannot pick it up off a shelf, and the brand’s own showcase photos come from people it paid. Treat them as advertising, not as a preview of your result.

Bimatoprost works by keeping more lashes in the growth phase

Each lash grows for a while, rests, then falls out and is replaced. Wisp’s product page says bimatoprost “increases eyelash thickness and length by increasing the percentage of hairs in the active growth phase” (Wisp). In other words, more of your lashes are growing at any one time.

That explanation comes from a seller, not an independent body. It does tell you why nothing shows up overnight: the effect builds as each lash moves through its cycle.

Both sellers put the full claim at 16 weeks; “4 weeks” is Wisp’s first step

Latisse’s site says: “For people with not enough lashes, LATISSE® grows FULLER, LONGER, DARKER LASHES AT 16 WEEKS” (Latisse.com). The same page says lashes were measured “at 16 weeks in the clinical study”. The “Paid users” caveat applies to the photos, not to that study.

Wisp’s headline is earlier. It says to start now “to begin seeing results in as little as 4 weeks” (Wisp). Further down the same page, Wisp sets out a ladder at 4, 8, 12 and 16 weeks that ends at “106% fuller lashes” at week 16. So the two sellers agree: 16 weeks is the point to judge the result.

Wisp’s own ladder: 16% at week 4 ÷ 106% at week 16 ≈ 0.15. By Wisp’s figures, the 4-week mark shows about 15% of the 16-week result, and Latisse’s site also places its claim at 16 weeks.

The flaw in Wisp’s page is the headline itself. “As little as 4 weeks” describes the first step, not the result the ladder ends on. Plan around 16 weeks with either product.

Generic bimatoprost has the same 0.03% active ingredient, “starting at $28”

Wisp sells bimatoprost 0.03% as generic Latisse. Its page says “Starting at $28”, as a one-time order or a subscription (Wisp, checked October 2026). The page does not list the bottle volume, so no price per mL can be worked out from it. The AAO lists Latisse at the same 0.03% strength (AAO). For the brand, Latisse.com offers an online prescriber consultation and Allē savings (Latisse.com). It does not give a price to set against Wisp’s $28.

Here is what each of the three routes involves before you pay:

	Brand Latisse	Generic bimatoprost (Wisp)	OTC isopropyl cloprostenate serums
Prescription needed	Yes: “PRESCRIPTION ONLY” (Latisse.com)	Yes, through an online prescriber	No, sold over the counter
Active ingredient	Bimatoprost ophthalmic solution, 0.03% (AAO)	Bimatoprost 0.03% (Wisp)	Isopropyl cloprostenate
FDA status	Bimatoprost is FDA approved (AAO)	Same active ingredient, which is FDA approved (AAO)	Not FDA approved (AAO)
Timeline the source gives	Fuller, longer, darker lashes at 16 weeks (site claim)	“As little as 4 weeks” to begin; ladder ends at “106% fuller lashes” at 16 weeks	Not FDA tested, so effects are not known (AAO)
Price or access	Online prescriber consultation and Allē savings on Latisse.com	“Starting at $28”, one-time or subscription; volume not listed (checked Oct 2026)	Set by each brand; check its price page
Side-effect warning	Iris darkening that cannot be reversed; eye redness, irritation, darker eyelid skin (AAO)	Not listed separately; the AAO page is written about Latisse (bimatoprost 0.03%)	Safety not known (AAO); read the brand’s own warning
How the FDA views it	A drug	A drug	A claim to restore hair growth can make a product a drug, even if it is sold as a cosmetic (FDA)

The ingredient and strength match. Latisse.com gives no price, so the two cannot be compared on cost from these pages.

Iris darkening is permanent; redness and lid darkening fade

The AAO reports darkening of the iris, “the colored portion of the eye,” and says “this side effect cannot be reversed” (AAO). The same page lists eye redness, irritation and darkening of the eyelid skin. The AAO says those go away once you stop using it.

Who should skip it: anyone under 18, since the AAO says Latisse is not approved for that age; anyone pregnant or breastfeeding, where the AAO says it is not recommended; and anyone who won’t accept a permanent change in eye color. For those readers, false lashes or extensions are the fit. The FDA puts them, and their adhesives, in the cosmetics category (FDA). Their own trade-off: they add lashes on top of yours and only last as long as they stay on.

So the prescription route has two real costs: a permanent iris risk and a 16-week wait. What it gives you in return is an FDA-approved active ingredient and a prescriber, where the AAO says the safety and effects of OTC serums “are not known”. Take it if you accept the iris risk, brand or generic. If you don’t, buy false lashes instead.

OTC isopropyl cloprostenate serums are not FDA approved, and their safety is unknown

The AAO says bimatoprost is FDA approved, but isopropyl cloprostenate, the analog often used in over-the-counter serums, is not (AAO). Its reason: “Because these over-the-counter serums have not been FDA tested, their safety and effects are not known.”

That is a statement about FDA testing, not a finding that these serums are harmful. If an OTC ingredient list shows isopropyl cloprostenate, you are using a prostaglandin analog without a prescriber, so read that brand’s own warning before you buy.

Under FDA rules, a hair-growth claim can make a product a drug

The FDA says “certain claims may cause a product to be considered a drug, even if the product is marketed as if it were a cosmetic,” and gives claims to restore hair growth as an example (FDA). The product does not decide which category it falls in. The claim does.

For a lash serum box, that means the words matter: a cosmetic serum describes how lashes look, while a promise to restore growth is the kind of claim the FDA ties to drugs, the category Latisse sits in.

For more on this topic, see the Lash serums guides.

FAQ

Is generic bimatoprost the same as Latisse? It has the same active ingredient at the same strength. Wisp sells bimatoprost 0.03% as generic Latisse (Wisp), and the AAO lists Latisse as bimatoprost ophthalmic solution, 0.03% (AAO).

Can I pay with FSA or HSA money? At Wisp, yes. Its product page says FSA and HSA payments are accepted (Wisp).

What if I wear contact lenses? The AAO says to take them out before you apply it and wait 15 minutes before putting them back in (AAO).